News & Updates

Show Multimedia Only
Osimertinib linked to cardiac events in NSCLC patients Osimertinib linked to cardiac events in NSCLC patients

Osimertinib linked to cardiac events in NSCLC patients

26 Nov 2025 byStephen Padilla

Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.

26 Nov 2025